Algert Global LLC reduced its stake in Embecta Corp. (NASDAQ:EMBC – Free Report) by 31.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 105,041 shares of the company’s stock after selling 48,912 shares during the quarter. Algert Global LLC’s holdings in Embecta were worth $1,481,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Public Employees Retirement System of Ohio raised its holdings in Embecta by 1,135.6% in the 1st quarter. Public Employees Retirement System of Ohio now owns 40,268 shares of the company’s stock valued at $534,000 after acquiring an additional 37,009 shares during the period. Vanguard Group Inc. increased its holdings in shares of Embecta by 2.7% during the first quarter. Vanguard Group Inc. now owns 7,213,992 shares of the company’s stock worth $95,730,000 after purchasing an additional 187,916 shares during the period. Jennison Associates LLC bought a new position in shares of Embecta during the third quarter worth approximately $594,000. AXA S.A. bought a new position in shares of Embecta during the second quarter worth approximately $1,595,000. Finally, AQR Capital Management LLC increased its holdings in shares of Embecta by 136.2% during the second quarter. AQR Capital Management LLC now owns 614,645 shares of the company’s stock worth $7,683,000 after purchasing an additional 354,454 shares during the period. 93.83% of the stock is owned by institutional investors.
Embecta Trading Up 10.1 %
Shares of EMBC opened at $20.59 on Friday. Embecta Corp. has a 12 month low of $9.93 and a 12 month high of $20.80. The firm’s 50 day moving average is $14.48 and its 200-day moving average is $14.11. The stock has a market capitalization of $1.19 billion, a PE ratio of 17.16 and a beta of 0.97.
Embecta Announces Dividend
Wall Street Analyst Weigh In
Separately, BTIG Research raised shares of Embecta from a “neutral” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Wednesday.
Get Our Latest Stock Analysis on EMBC
Embecta Profile
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Further Reading
- Five stocks we like better than Embecta
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- What Does a Stock Split Mean?
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Want to see what other hedge funds are holding EMBC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Embecta Corp. (NASDAQ:EMBC – Free Report).
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.